492 related articles for article (PubMed ID: 19860731)
1. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
4. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
Prodromou C
Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
[TBL] [Abstract][Full Text] [Related]
5. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action.
Matts RL; Manjarrez JR
Curr Top Med Chem; 2009; 9(15):1462-78. PubMed ID: 19860729
[TBL] [Abstract][Full Text] [Related]
6. Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
Gao J; Zhou C; Zhong Y; Shi L; Luo X; Su H; Li M; Xu Y; Zhang N; Zhou H
Biochem Pharmacol; 2023 Jan; 207():115376. PubMed ID: 36513142
[TBL] [Abstract][Full Text] [Related]
7. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
8. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
9. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
10. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
11. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.
Li Y; Zhang T; Schwartz SJ; Sun D
Drug Resist Updat; 2009; 12(1-2):17-27. PubMed ID: 19179103
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
14. Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
Gavenonis J; Jonas NE; Kritzer JA
Bioorg Med Chem; 2014 Aug; 22(15):3989-93. PubMed ID: 24984936
[TBL] [Abstract][Full Text] [Related]
15. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
16. Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines.
Lee T; Seo YH
Bioorg Med Chem Lett; 2013 Dec; 23(23):6427-31. PubMed ID: 24125885
[TBL] [Abstract][Full Text] [Related]
17. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibition with resorcyclic acid lactones (RALs).
Winssinger N; Fontaine JG; Barluenga S
Curr Top Med Chem; 2009; 9(15):1419-35. PubMed ID: 19860733
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
20. Selective Inhibition of the Hsp90α Isoform.
Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]